Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M

Absci Corp

2026-Q1 EPS reported -$0.19 revenue$215,000

Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.
Initiated MAD dosing in AGA participants; preliminary PK supports 2-3 injections over six months.
Expanded pipeline with ABS-202, a novel anti-PRLR antibody for undisclosed I&I indication.
Q1 revenue $0.2M, net loss $29.6M; cash $125.7M sufficient into first half of 2028.
Anticipates reporting preliminary safety, tolerability, PK data in Q2 2026; proof-of-concept in H2 2026.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Absci Corp reported first quarter ended March 31, 2026 results: revenue $0.2 million.

Period: first quarter ended March 31, 2026
Revenue: $0.2 million
Result: reported results

Exact text from the filing

Revenue was $0.2 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Absci Corp filing history →

Source: SEC EDGAR

accession 0001672688-26-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.